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Abstract
The 90K protein, also known as Mac-2 BP or LGALS3BP, can activate the immune response in part by increasing major
histocompatibility (MHC) class I levels. In studies on a non-immune cell model, the rat FRTL-5 cell line, we observed
that transforming growth factor (TGF)-β1, like γ-interferon (IFN), increased 90K levels, despite its immunosuppressive
functions and the ability to decrease MHC class I. To explain this paradoxical result, we investigated the mechanisms
involved in the TGF-β1 regulation of 90K expression with the aim to demonstrate that TGF-β1 utilizes different
molecular pathways to regulate the two genes. We found that TGF-β1 was able to increase the binding of Upstream
Stimulatory Factors, USF1 and USF2, to an E-box element, CANNTG, at −1926 to −1921 bp, upstream of the interferon
response element (IRE) in the 90K promoter. Thyrotropin (TSH) suppressed constitutive and γ-IFN-induced 90K
expression by decreasing USF binding to the E-box. TGF-β1 was able to overcome TSH suppression at the
transcriptional level by increasing USF binding to the E-box. We suggest that the ability of TGF-β1 to increase 90K did
not result in an increase in MHC class I because of a separate suppressive action of TGF-β1 directly on the MHC class I
gene. We propose that the increased levels of 90K may play a role, rather than in immune response, in the context of
the TGF-β1-induced changing of the cellular microenvironment that predisposes to cell motility and cancer
progression. Consistently, analyzing the publicly available cancer patient data sets cBioPortal, we found that 90K
expression directly correlated with TGF-β1 and USFs and that high levels of 90K were significantly associated with
increased mortality in patients affected by different types of cancer.
Introduction
The Transforming growth factor-beta (TGF-β) poly-
peptides regulate the growth, function, and immune
properties of cells1. The prevalent role of TGF-β1 in the
immune system is to induce tolerance and immune sup-
pression2, in part by inhibiting IL-2 production and NK
activity3,4, promoting the differentiation of naive T-cells
into Treg via Foxp3 transcription factor5,6, and decreasing
the expression of major histocompatibility complex
(MHC) class I7. The importance of suppressing class I
levels is clear since TGF-β1-deficient transgenic mice
have increased MHC class I levels in many organs and
develop a rapid, wasting, autoimmune disease8.
The 90K protein, also known as Mac-2 BP or
LGALS3BP, is an oligomeric glycoprotein that has been
identified in the serum of patients with tumors or acquired
immunodeficiency syndrome (AIDS)9. In contrast to TGF-
β1, 90K activates the immune defense systems of the
organism10. In particular, human 90K enhances the in vitro
generation of cytotoxic effector cells (NK and LAK) from
peripheral blood mononuclear cells (PBMC)11; increases
IL-2 production by PBMC11 and increases MHC class I
antigen expression in human breast cancer cells12.
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To better understand the physiological role of 90K, we
have characterized its function in rat FRTL-5 thyroid
cells. These cells were chosen because they can maintain a
normal functioning behavior in culture: (i) near diploid,
(ii) absence of tumor phenotype, (iii) growth and
immune-related protein expression under the control of
TSH13. In FRTL-5 cells, we have previously reported that
rat 90K, similarly to its human homologous, was increased
by γ-IFN and that TSH was able to decrease both con-
stitutive and γ-IFN-induced 90K synthesis14. We have
also shown that rat 90K acted in an autocrine or para-
crine/exocrine manner to increase MHC class I and that it
was a component of an immune response aimed at con-
verting non-immune cells to potential antigen-presenting
cells (APCs)14. This effect was triggered by the presence of
foreign double-strand nucleic acids in the cytoplasm
(viral, bacterial, or self)14.
As expected, in rat FRTL-5 thyroid cells TGF-β1
decreases expression of MHC class I15 and inhibits cell
proliferation as well as the thyrotropin (TSH)-induced
functions such as iodide uptake and thyroglobulin
production16,17.
Thus, given the antagonistic properties of TGF-β1 and
90K within the immune system and their opposite effects
on MHC class I regulation in FRTL-5 cells, we investi-
gated the effect of TGF-β1 on the expression of 90K.
Surprisingly, we found that TGF-β1-increased 90K gene
expression.
In the present study, we investigated the mechanism
by which this occurred in the attempt to explain the
apparent paradox and better clarify the biologic function
of 90K.
Material and methods
Cells
Rat FRTL-5 thyroid cells (Interthyr Corporation, Mar-
ietta, OH, USA) were a fresh subclone (F1) with all
properties described18. They were grown in 6H medium
consisting of Coon’s modified F12 medium, 5% heat-
treated, mycoplasma-free, calf serum, 1 mM nonessential
amino acids, and a six hormone mixture: bovine TSH (1 ×
10−10M), insulin (10 μg/ml), cortisol (0.4 ng/ml), trans-
ferrin (5 μg/ml), glycyl-L-histidyl-L-lysine acetate (10 ng/
ml), and somatostatin (10 ng/ml). Cells were fed every
2–3 d, were passaged every 7–10 d, were diploid and were
between their fifth and 25th passage. Their doubling time
with TSH was 36 ± 6 h; without TSH, they did not pro-
liferate nor exhibit most thyroid-specific functions. As
noted, in some experiments cells were maintained in 5H
medium (no TSH) then stimulated with 1 × 10−10 M
TSH, 100 U/ml rat γ-IFN, or 5 ng/ml TGF-β1 for 24 h
unless otherwise noted. Experiments carried out using
forskolin (5 μM) and IGF-I (100 ng/ml) instead of TSH
and insulin, respectively, showed similar results.
U2OS cells (ATCC® HTB-96TM), a human osteo-
sarcoma cell line suitable for co-transfection experi-
ments, were grown in Dulbecco’s Modified Eagle’s
Medium with 4.5 g/l glucose, supplemented with 10%
fetal bovine serum, 1% Pen/Strep and 1% L-glutamine
(Merck, Darmstadt, Germany).
RNA isolation, northern blot analysis, and RT-qPCR
For northern blot, RNA was isolated using the com-
mercial kit Quickprep mRNA Purification (Pharmacia
Biotech, Uppsala, Sweden) and northern analysis was
performed using Nytran nitrocellulose membranes
(Merck, Darmstadt, Germany) as described14. Filters were
hybridized with the rat 90K and GAPDH cDNAs;
radiolabeling of probes and hybridization (1 × 106 cpm/
ml) were also as described14. Rat 90K cDNA was the
full-length clone previously described14.
For reverse transcription-quantitative PCR (RT-qPCR),
total RNA was isolated using QIAzol Lysis Reagent
(Qiagen, Hilden, Germany) according to the manu-
facturer’s instruction and reverse-transcribed with the
High Capacity cDNA Reverse Transcription Kit (Ther-
moFisher Scientific, Waltham, Massachusetts, USA). RT-
qPCR was performed using the QuantiFast SYBR® Green
PCR Kit (Qiagen, Hilden, Germany) using specific rat 90K
primers, F: 5′-CTGAACAGTCTACAGAAAGCTTCG-3′
and R: 5′-GACCTGGAAGCCCAACCT-3′; and GAPDH
primers, F: 5′-TGGGAAGCTGGTCATCAAC-3′ and R:
5′-GCATCACCCCATTTGATGTT-3′. Melting curve
analyses were performed according to the specification of
the CFX96 Touch™ Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA). 90K mRNA expression
was normalized to the endogenous reference GAPDH
using the 2-Δct method (User Bulletin #2, ThermoFisher
Scientific, Waltham, Massachusetts, USA).
In vivo labeling and immunoprecipitation
FRLT-5 cells in 5H medium were stimulated with 1 ×
10−10 M TSH, 100 U/ml rat γ-IFN, or 5 ng/ml TGF-β1 as
noted above. Biosynthetic labeling of proteins was
performed during the last 12 h by maintaining the
cells overnight with 35S-methionine (50 μCi/ml) in
methionine-free F12 Coon’s modified medium (0.5 ml/
well) containing 1% dialyzed FCS (ThermoFisher Scien-
tific, Waltham, MA, USA). The spent medium was pre-
cleared with rabbit preimmune serum and incubated with
the polyclonal anti-90K antibody14, followed by protein
A-Sepharose (Merck, Darmstadt, Germany). The immu-
noprecipitate was separated by SDS-PAGE and proteins
detected by autoradiography.
Oligonucleotides and plasmids
USF expression plasmids (pUSF1 and pUSF2) were gen-
erated by cloning USF1 or USF2 DNA into pCMV-tag2A
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vectors (Agilent Technologies, Santa Clara, CA, USA), as
previously described19. The rat 90K promoter-luciferase
chimera, containing the fragment spanning position −1963
to −1772 bp of the 90K 5′-flanking region subcloned in a
pGL3 basic vector (Promega, Madison, WI, USA), was also
described14. This region referred to as P2, corresponds to the
minimal promoter defined by sequence homology among
rat, human, and mouse genes and is functionally relevant as
it contains the interferon and TSH response elements20.
Using site-specific PCR mutagenesis procedure, we created a
P2 fragment with four base substitutions in the interferon
response element (IRE) (−1912 to −1902 bp). This con-
struct, indicated as P2IREM, has the IRE sequence changed
in tcA gCt GAA GCT and was also subcloned in a pGL3
basic vector (Promega, Madison, WI, USA).
Oligo I–II is the region spanning from −1963 to −1912
bp in the rat 90K minimal promoter; Oligo II is from
−1963 to −1932: 5′-AGC CTT GTC TGC AGC CAA
CCC CAG AGG CAG CC-3′; Oligo I is from −1937 to
−1912 bp: 5′-GCA GCC TCC GTC ATG TGT TTT CTG
GA-3′. CM3, CM2, CM1, TM1, TM2, and CEM are two-
base substitutions of Oligo I: CM3, 5′-GCA aCa TCC
GTC ATG TGT TTT CTG GA-3′; CM2, 5′-GCA GCa
TCa GTC ATG TGT TTT CTG GA-3′; CM1, 5′-GCA
GCC TCa GgC ATG TGT TTT CTG GA-3′; TM1, 5′-
GCA GCC TCC GTC ATc TGT TTc CTG GA-3′; TM2,
5′-GCA GCC TCC GTC ATG TGT TTc aTG GA-3′; and
CEM, 5′-GCA GCC TCC GTC ATG gaT TTT CTG GA-
3′. Lowercase and bold letters denote the substituted
nucleotides. The oligonucleotide containing the con-
sensus E-box binding site (bold and underlined), indicated
as E, is 5′-GGA AGC AGA CCA CGT GGT CTG CTT-3;
EM is a two-base mutation (lowercase) in the E-box of E,
5′-GGA AGC AGA CCA CGg aGT CTG CTT-3′. The
cAMP response element (CRE) competitor was 5′-AGA
GAT CTG ACG TCA GAC AGC TAG-3′; the FAST-1
binding element (FBE) competitor was 5′-CTG CCC TAA
AAT GTG TAT TCC TAG GAA ATG 3′. The double-
strand oligonucleotides used for gel mobility shift assay
were obtained by annealing each oligonucleotide with its
complementary antisense strand.
Oligo I–II, Oligo II, or Oligo I, with and without
mutations, were also subcloned into a pGL3 promoter-
luciferase reporter gene vector containing the
SV40 minimal promoter (Promega, Madison, WI, USA).
To construct the human 90K minimal promoter-
luciferase chimera (pGL3_hu90K) the fragment span-
ning from −115 to +42 of the human 90K 5′-flanking
region (sequence number based on defining transcrip-
tional start site as +1) was generated by PCR using the full
length 90K promoter present in the pBluescript II KS (+)
vector (a gift of Prof. Axel Ullrich, Max Plank Institutes,
Munich, Germany)21 as template, the sequence 5′-CCG
CTC GAG TGG GGA GTA TCA GCA GCA G-3′ as
forward primer, and the sequence 5′-TAC CAA CAG
TAC CGG AAT GC-3′ as reverse primer. The fragment
was subcloned in pGL3 basic vector (Promega, Madison,
WI, USA) at the XhoI and HindIII insertion sites.
Transient expression
Transient transfections in FRTL-5 cells used a DEAE
procedure22 and were performed as described20. Trans-
fections used 2 μg of the pGL3 basic luciferase reporter
gene or equivalent molar amounts of pGL3 containing the
P2 rat 90K constructs with or without IRE mutation
(P2IREM). pSVGH, 5 μg, was added to measure transfec-
tion efficiency. In some experiments, cotransfections were
performed using 3 μg of pUSF1, pUSF2, or the control
vector pCMV-tag2A. In other experiments, the same pro-
cedure was used to transfect cells with 2 μg of the SV40-
driven pGL3 luciferase reporter vector or equivalent molar
amounts of this vector containing Oligo I–II, Oligo II, or
Oligo I with or without the above-indicated mutations.
After transfection, cells were maintained 3–6 h in 6H
medium and then shifted to 5H medium with no TSH.
After 24 h in the 5H medium, cells were treated with TSH
(1 × 10−10M), γ-IFN (100 U/ml), or TGF-β1 (5 ng/ml).
Luciferase activity was assayed after 24 h. Values were
normalized for total cell protein and growth hormone
activity. The activity of the empty vector was considered as
the control value unless otherwise noted.
Transfections of pGL3_hu90K were performed in U2OS
cells using Lipofectamine 2000 reagent (ThermoFisher
Scientific, Waltham, Massachusetts, USA). Briefly, 10,000
cells were co-transfected with the pGL3_hu90K or the
empty vector (150 ng), in the presence or not of pUSF1 or
pUSF2 vector (150 ng) and the Renilla luciferase reporter
vector pRLTK (15 ng) (Promega, Madison, WI, USA).
After 24 h, firefly luciferase activity was measured and
normalized to that of Renilla using the Dual-Luciferase
Reporter Assay System according to the manufacturer’s
instructions (Promega, Madison, WI, USA).
Nuclear extracts
To prepare nuclear extracts, FRTL-5 cells were grown
in a complete 6H medium until 50–70% confluent. Cells
were shifted in 5H medium with no TSH for 5 days and
then stimulated with γ-IFN (100 U/ml), TSH (1 × 10−10
M), TGF-β1 (5 ng/ml), or combinations thereof for the
times noted, usually 24 h. Nuclear extracts were prepared
as described20. Protein concentration was determined by
Bradford’s method (Bio-rad, Hercules, CA, USA) with
crystalline bovine serum albumin (BSA) as standard. The
extracts were aliquoted and stored at −70 °C.
Electrophoretic mobility shift assay (EMSA)
DNA probes were the oligonucleotides described above.
They were 5′ labeled with [γ-32P]ATP using T4
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polynucleotide kinase (New England Biolabs). Binding
reactions, 20 μl in volume, included 5 μg nuclear extract,
2% glycerol, 50 ng/ml polydI-dC, and 2mM DTT in
Binding Buffer: 20 mM HEPES, 0.1% NP40, 5 mM MgCl2,
and 50mM KCl. Where indicated, specific antisera
(0.4 ng) or unlabeled oligonucleotide competitors (20× or
50× the concentration of labeled probe) were added for
15min at room temperature. Reactions were initiated by
adding 50,000 cpm labeled DNA probe; after 15 min at
room temperature, samples were electrophoresed at
160 V on 5% native polyacrylamide gels in 1×TBE at room
temperature. Gels were dried and autoradiography
performed.
USF1 production in Escherichia coli
Recombinant USF1 was produced using the pET system
(Merck, Darmstadt, Germany). The USF1 cDNA was
subcloned into the EcoRI site of the expression vector
pET-30(+), allowing the His-Tag sequence to be linked to
its N terminus. The protein was produced in E. coli BL21
(DE3) after a 4-h stimulation with 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and purified according to
the manufacturer’s procedures under reducing conditions.
Purified USF1 was dialyzed against 20 mM HEPES, 0.1%
NP40, 5 mM MgCl2, 50 mM KCl, 2% glycerol, 2 mM
DTT, and concentrated in a Centricon 10 (Amicon,
Beverly, MA, USA) to be used in EMSA. The purity
and integrity of the recombinant protein were verified by
SDS/PAGE.
Analysis of public platforms for ChIP-seq and clinical data
To confirm the binding of USFs in the promoter
region of the human 90K gene, we analyzed the publicly
available ChIP-seq (chromatin immunoprecipitation
followed by high-throughput sequencing) database
generated by the ENCODE consortium, freely accessible
at https://www.encodeproject.org/. The ChiIP-seq
experiments were carried out on the human embryo-
nic cell H1.
The cBioPortal platform, publicly available at https://
www.cbioportal.org/, was analyzed to correlate 90K (both
mRNA and protein) with TGF-β1 and USFs expression
and to investigate the relationship between 90K levels and
overall survival (OS) in patients affected by different types
of cancer.
Statistical significance
All experiments were repeated at least three times with
different batches of cells. Values were the mean ± SD of
these experiments where noted. Significance between
experimental values was determined by a two-tailed Stu-
dent’s t-test or two-way analysis of variance and was
significant if p values were <0.05 when data from all
experiments were considered.
Materials
Highly purified bovine TSH was obtained from the
hormone distribution program of the National Institute of
Diabetes and Digestive and Kidney Diseases, National
Institutes of Health (NIDDK-bTSH I-1; 30 U/mg). Rat γ-
IFN was from Amgen (Thousand Oaks, CA, USA);
recombinant IGF-I was from the Fujisawa Pharmaceutical
Co. (Chūō, Tokyo, Japan). Antibodies against USF1 or
USF2 were from Santa Cruz Biotechnology, Inc. (Dallas,
TX, USA). Human platelet TGF-β1 was from Merck
(Darmstadt, Germany). [γ-32P]ATP (3000 Ci/mmol) was
from Amersham (Arlington Heights, IL, USA). The
source of other materials was Merck (Darmstadt, Ger-
many) unless otherwise noted.
Results
TGF-β1-increased 90K RNA levels and protein secretion
Although FRTL-5 cells maintained in medium without
TSH (5H medium) had a considerable expression of 90K
mRNA detectable by RT-qPCR (Fig. 1A, bar 1), the
addition of 5 ng/ml of TGF-β1 to the medium caused a
significant increase in 90K mRNA levels (Fig. 1A, bar 2 vs
1). When 1 × 10−10M TSH was added to the 5H medium,
there was, in contrast, a significant decrease in 90K
mRNA levels (Fig. 1A, bar 4 vs 1), as previously repor-
ted14. The addition of TGF-β1 overcomes the suppressive
action of TSH, increasing 90K RNA levels to the same
extent of that observed when TGF-β1 was added to 5H
medium (Fig. 1A, bar 5 vs 2).
The increase in 90K mRNA induced by TGF-β1 was as
prominent as that induced by γ-IFN (Fig. 1A, bar 3 vs 1
and bar 6 vs 4), particularly in 6H cells because TSH, in
the presence of insulin, reduces the γ-IFN effect, as pre-
viously reported14. RT-qPCR data were confirmed by
northern blot analysis (see Fig. 1SA, B in Supplementary
Materials).
Autoradiography of [35S]methionine-labeled proteins
secreted by FRTL-5 cells and immunoprecipitated with a
specific anti-90K antibody revealed the presence of a high
molecular weight form of 90K (~200 kDa) and one of
~57 kDa, when cells were grown in 5H medium (Fig. 1C,
lane 1). High molecular weight dimers of 90K protein
have been identified by western blotting in studies on
human fluids11 and the mechanisms involved in dimer-
ization or oligomerization have been detailed23. The 200-
and 57-kDa bands are likely corresponding to 90K dimers
and protein degradation products, respectively. In some
experiments, in 5H medium, a tiny band at ~90 kDa was
also appreciable, corresponding to the 90K monomer14.
Cells incubated with γ-IFN or TGF-β1 for 24 h (Fig. 1C,
lane 2 and 3, respectively) secreted a prominent ~90 kDa
form, as well as an increased amount of the high
molecular weight 200 kDa form of the 90K protein.
The ~57 kDa form appeared increased, albeit slightly
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decreased in size. Moreover, an additional 47 kDa form
appeared in the medium from γ-IFN-treated cells (Fig. 1C,
lane 2). The increase in 90K secretion (monomer and
dimer) was consistent with the effect of TGF-β1, as well as
γ-IFN, to increase mRNA levels and protein synthesis,
while that of 57- and 47-kDa forms was consistent
with increased degradation of 90K in association with
increased synthesis and secretion.
The addition of TSH to cells in a medium containing
insulin (6H vs 5H), significantly decreased secretion of the
~200 kDa form of the protein and increased the amounts
of lower molecular weight forms (Fig. 1C, lanes 4 to 6).
This was consistent with increased degradation of 90K in
the presence of TSH, whether synthesis was increased by
TGF-β1 or γ-IFN. Thus, TSH does not affect TGF-β1-
induced 90K RNA levels but increases 90K protein
degradation.
Identification of the TGF-β1 responsive element in the
minimal 90K functional promoter
We measured the activity of the rat 90K minimal pro-
moter by luciferase assay as described previously20, using
the construct containing the fragment spanning position
−1963 to −1772 bp of the 90K 5′-flanking region (P2
construct) (Fig. 2, middle diagram). After transfection,
FRTL-5 cells were maintained in 5H medium and sti-
mulated with 5 ng/ml TGF-β1, 100 U/ml γ-IFN, or 1 ×
10−10 M TSH (Fig. 2A). We observed that the luciferase
activity of the construct in response to TGF-β1 or γ-IFN
mimicked the effects of both on RNA levels (Fig. 2A vs
Fig. 1B). Based on the activity of the P2 construct, we
concluded that TGF-β1 acted on the same minimal pro-
moter that was sensitive to γ-IFN and TSH. This region
includes the IRE and corresponds to the minimal pro-
moter defined by sequence homology between rat,
human, and mouse genes20.
The insertion of 4 bp mutations in the IRE of the P2-
luciferase construct (P2IREM) (Fig. 2, upper diagram)
abolished the ability of γ-IFN to increase promoter
activity (Fig. 2B, bar 2 and 6), but did not influence sig-
nificantly the effect of TGF-β1 or TSH (Fig. 2B, bar 7 and
5, respectively), indicating that TGF-β1 activity was not
mediated by the IRE.
The sequence of P2 upstream of the IRE, termed Oligo
I–II, was inserted into a pGL3 vector with a SV40 pro-
moter (Fig. 2, lower diagram). In 5H medium, the Oligo
I–II construct had a significant constitutive activity
compared with its control vector without the insert
(Fig. 2C, bar 1). TSH significantly decreased constitutive
activity (Fig. 2C, bar 2). TGF-β1, but not γ-IFN, overcame
the TSH-induced decrease in promoter activity (Fig. 2C,
bar 4 vs 3). The Oligo I–II region was, therefore, the TSH
and TGF-β1 site of action.
By inserting Oligo I wild type (−1937 to −1912) or Oligo
I with 2 bp mutations into a pGL3 promoter, we had pre-
viously determined the site for constitutive 90K expression
and TSH suppression20. Similarly, we could localize the
TGF-β1 action within this region. Coordinate results
were obtained when vector constitutive activity was eval-
uated simultaneously for TGF-β1- or TSH-responsiveness.
Fig. 1 Effect of TGF-β1 on rat 90K mRNA and protein secretion in FRTL-5 cells. In A, RT-qPCR analyses to characterize the effect of TGF-β1 and
γ-IFN on 90K mRNA expression in the presence or absence of TSH. In B, autoradiography of biolabeled secreted proteins immunoprecipitated by
specific anti-90K serum. A single asterisk (*) denotes a significant decrease (p < 0.05); two asterisks (**) or three asterisks (***) denote a significant
increase (p < 0.01 and p < 0.001, respectively). Data represent the mean ± SD of duplicate values determined in three separate experiments
performed on different batches of cells.
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In particular, as was the case for TSH-suppressive activity,
the increased response to TGF-β1 was present in Oligo I
construct, but was lost, along with constitutive activity, in
the constructs containing mutations between −1929 and
−1917 bp (CM1 and TM1) (Fig. 2D). The promoter activity
exhibited by Oligo I and CM2, CM3, TM2 mutants were
similar, as was their TGF-β1 and TSH response (Fig. 2E).
Since mutant CM1 lost both activities as did TM1, but not
TM2, CM2, nor CM3, it was evident that the critical resi-
dues for constitutive activity and for both TGF-β1 or TSH
activity involved the sequence spanning −1929 to −1917
bp, and did not involve the 5′ nucleotide mutation in
CM1 (C-1929A) and the 3′ nucleotide mutation in TM1
(T-1917C).
We preliminarily interpreted these data as follows. An
element important for the constitutive activity of the rat
90K minimal promoter existed between −1929 and
−1917 bp. This same element was also important for both
TGF-β1-increased and TSH-decreased 90K activity.
EMSA data below support this interpretation and define
Fig. 2 Ability of TGF-β1 to increase promoter activity of rat 90K in FRTL-5 cells. In the upper diagram, the sequence of the rat 90K minimal
promoter, P2 fragment, or the same construct with 4 bp mutations in the interferon response element (IRE), P2IREM, are depicted as inserted in a
pGL3 basic luciferase reporter vector. The IRE is boxed to show the mutated nucleotides (lowercase letters). Luciferase activity was normalized for
protein and growth hormone activity. In A, luciferase activity of the P2 construct. In B, luciferase activity of the P2IREM construct. In the lower
diagram, the region between −1963 and −1912 bp upstream of the IRE, termed Oligo I–II, or the region between −1937 and −1912, termed Oligo I,
or 5 different constructs with 2 bp mutations, were subcloned in a pGL3 promoter-luciferase reporter vector. Luciferase activity was expressed as
relative to a control construct with no insert. In C, luciferase activity of Oligo I–II. In D, promoter activity of CM1 and TM1 is lost compared to Oligo I. In
E, promoter activity of CM3, CM2 and TM2 is similar to that of Oligo I. A single asterisk (*) denotes a significant decrease in promoter activity (p < 0.05);
two asterisks (**) or three asterisks (***) denote a significant increase in promoter activity (p < 0.05 and p < 0.01, respectively), a dark circle (●) denotes
a significant decrease in constitutive promoter activity (p < 0.05).
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the cis element as an E-box and the trans factors involved
as USF1 and USF2.
An E-box and USF transcription factors regulate
constitutive and TGF-β1-induced expression of rat 90K
As previously reported20, we performed EMSA to eval-
uate the effects of the CM1, CM2, CM3, TM1, and TM2
mutations on trans factor binding to the Oligo I region
defined functionally as important for constitutive as well
as TGF-β1-enhanced or TSH-suppressed 90K activity
(Fig. 3A). A prominent protein/DNA complex was noted
incubating radiolabeled Oligo I with nuclear extracts of
cells maintained in 5H medium (Fig. 3A, lane 1). This
complex was nearly eliminated in incubations with radi-
olabeled CM1 or TM1 oligonucleotides (Fig. 3A, lanes 2
and 5, respectively) but was unaltered using radiolabeled
CM3 or CM2 oligonucleotides (Fig. 3A, lanes 3 and 4). The
complex was only partly attenuated in incubations with
radiolabeled TM2 oligonucleotide (Fig. 3A, lane 6).
More importantly, formation of the complex was
increased in extracts from cells treated with 5 ng/ml TGF-
β1 (Fig. 3B, lane 3 vs 2), but decreased in extracts from
cells treated with TSH (Fig. 3B, lane 4 vs 2).
The sum of these data suggested that the presence of
this complex was important for constitutive 90K gene
expression, was increased by TGF-β1, but was decreased
by TSH.
In reviewing the sequence of Oligo I, we noted a
potential cyclic AMP responsive element (CRE) but found
no inhibition of the complex by an oligonucleotide with a
consensus CRE (Fig. 3C, lane 3). Similarly, we noted a
potential FAST-1 binding site but found no inhibition of
the complex by an oligonucleotide with a consensus
FAST-1 binding element (FBE) (Fig. 3C, lane 4). The
exclusion of FAST-1 as a potential binding site was
important given the extent of homology and given that
FAST-1 is involved in TGF-β1 signaling1.
We noted, however, a potential E-Box CANNTG at
−1926 to −1921 bp, and could show that binding of the
constitutive complex was not duplicated by an Oligo I
with a critical mutation in the potential E-box (CEM),
CATGga (mutation in bold and small letters), as was the
case for the CM1 oligonucleotide (Fig. 3D, lanes 3 and 2,
respectively, vs lane 1). Formation of a complex with the
same mobility was obtained with a radiolabeled oligonu-
cleotide with a consensus E-box (CACGTG) and no other
sequence homology to Oligo I (EWT) (see Fig. 3E, lines 5
and 6), but did not with the same oligonucleotide carrying
the E-box mutation CACGga (EM) (Fig. 3D, lane 4).
When used as competitors, both oligonucleotides, Oligo I
and EWT, were inhibitory at the same concentrations
(Fig. 3D, lanes 5 and 7 vs 1). In contrast, there was no
inhibition when EM was used as competitor (Fig. 3D, lane
6). These data supported the conclusion that the element
important for constitutive as well as TGF-β1-increased
90K activity of the rat 90K minimal promoter was an E-
box with the sequence CATGTG, consistent with the
known E-box site CANNTG.
The E-Box is known to bind the basic helix-loop-helix
zipper proteins, upstream stimulatory factors 1 and 2
(USF1 and USF2)24. When antisera to USF1 and USF2,
but not a control serum, were included in the assay, the
native complex was eliminated (low arrow) and super-
shifted complexes appeared (Fig. 3D, lanes 9 and 10 vs 8).
The increase in density of the complex, independent of
the sera added, was presumed to be a nonspecific salt
effect of the antisera buffer (Fig. 3D, lanes 8 to 10). Anti-
USF2 generated two supershifted complexes, the upper of
which was most prominent (Fig. 3D, lane 10, arrows).
Anti-USF1 appeared to generate a major supershifted
complex with the same mobility as the faster migrating
one supershifted by anti-USF2, and a smaller amount of
the upper complex (Fig. 3D, lane 9, arrows).
The ability of anti-USF1 and anti-USF2 to generate a
supershifted complex with the same mobility and to
completely eliminate the native complex suggested that
the latter was represented by a USF1/USF2 heterodimer.
The differences in the pattern of supershifted complexes
obtained with anti-USF1 and anti-USF2 suggested, how-
ever, that USF homodimers might also be interacting with
the E-box of the 90K gene in extracts from TGF-β1-
treated cells.
Using Oligo I or the unrelated EWT oligonucleotide
(Fig. 3E, EWT) as radiolabeled probes, we found com-
plexes with identical mobility in EMSA with nuclear
extracts from TGF-β1-treated cells (Fig. 3E, lanes 2 and
5). The same-sized complexes were also formed with
recombinant USF1 (Fig. 3E, lanes 4 and 6). More impor-
tantly, the addition of full-length pUSF1 or pUSF2 to
transfections enhanced the constitutive expression of P2,
eliminated the TGF-β1-induced increase, and nearly
completely attenuated the TSH-induced suppression of
constitutive P2 expression (Fig. 3F). This was not dupli-
cated by the control plasmid.
Given the high sequence homology between the rat and
human 90K minimal promoters, including the same loca-
ted IRE and E-box20, we would verify if USFs were able to
induce the human 90K gene. Co-transfection of U2OS cells
with pUSF1 or pUSF2 expression plasmids in the presence
of pGL3_hu90K significantly enhanced the luciferase
activity of the reporter vector (Fig. 3G), indicating a direct
effect of USF in inducing human 90K gene expression.
USFs bind the E-box in the promoter region of the human
90K gene
The ability of USFs to bind the E-box present in the
human 90K gene promoter was confirmed by analyzing
the ChIP-seq database generated by the ENCODE
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consortium. By selecting the human embryonic cell H1 as
Biosample and browsing the platform for USF1, as a
transcription factor, and human 90K (LGALS3BP), as the
target gene, a peak region in the LGALS3BP promoter
sequence of Chromosome 17 was identified in six differ-
ent experiments (Fig. 4, lower diagram). As expected, the
Fig. 3 (See legend on next page.)
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highest point of the peaks overlapped with the consensus
motif CANNTG binding site for USF (Fig. 4, upper
diagram).
Human 90K (LGALS3BP) levels directly correlate with
TGF-β1 and USFs expression and affect cancer patient
prognosis
The analysis of different cancer data sets included in the
public cBioPortal platform revealed a general association
between high tumor levels of LGALS3BP (both mRNA
and protein) and shorter survival in patients affected by
different types of cancer. The effect reached statistical
significance in some tumors such as breast cancer, col-
orectal cancer, and clear cell renal cell carcinoma
(ccRCC). The latter neoplasm showed the highest statis-
tical power in distinguishing prognosis between patients
with high and low LGALS3BP levels. In particular, in a
cohort of 512 patients with ccRCC included in the TCGA
PanCancer Atlas database, the median disease-specific OS
was significantly shorter in patients with high LGALS3BP
(EXP > 1) compared to those with low LGALS3BP (EXP <
1) (56.68 months vs not reached, p < 0.001) (Fig. 5A).
Similar results were observed among patients with high
(EXP > 1) and low (EXP < 1) TGF-β1 (median disease-
specific OS 53.42 vs 116.84 months, p < 0.001) (Fig. 5B),
and among patients with high (EXP > 1) or low (EXP < 1)
USF1 (median disease-specific OS 56.68 vs not reached,
p < 0.001) (Fig. 5C). Importantly, the magnitude of the
effect on survival was significantly increased when
patients with concomitant high LGALS3BP and high
TGF-β1 (HH) were compared with those with low
LGALS3BP and low TGF-β1 (LL), indicating a synergistic
effect between the two genes (Fig. 5D). Kaplan–Meier
curves showed that the group HH had significantly
shorter survival compared with the group LL (median
disease-specific OS 40.44 months vs not reached, p <
0.001) (Fig. 5D). Importantly, in tumor samples, the
expression levels of LGALS3BP showed a direct correla-
tion with those of TGF-β1 (R= 0.34, p < 0.001), USF1
(R= 0.30, p < 0.001), and USF2 (R= 0.37, p < 0.001)
(Fig. 5E). In addition, in cancer cells, there was a strong
tendency of co-occurrence between high LGALS3BP, high
USF1, high USF2, and high TGF-β1 expression (p < 0.001)
or low LGALS3BP, low USF1, low USF2, and low TGF-β1
expression (p < 0.001) (Fig. 5F). Overall, clinical data
support a direct relationship between the activation of the
TGF-β1/USFs/90K axis and poor prognosis.
Discussion
In this study, we showed that TGF-β1 increases 90K
gene expression by increasing USF1 and USF2 binding to
its promoter, in the same E-box involved in the hormonal
regulation of the gene.
In fact, we previously demonstrated that USF1 and
USF2 were the relevant transcription factors controlling
constitutive 90K expression and that TSH was able to
decrease 90K expression by reducing USFs binding to the
E-box20.
Taken together, this and our previous report suggest
that 90K gene expression depends on the interaction of
the E-box located in its promoter with USF1 and USF2,
and that this interaction is regulated by TGF-β1 and
TSH: TGF-β1 increments USF binding to the E-box
and increases 90K gene expression, while TSH reduces
USF binding to the E-box and decreases 90K gene
expression.
(see figure on previous page)
Fig. 3 Identification of a specific complex binding to the rat 90K minimal promoter important for TGF-β1-induced or TSH-suppressed
expression of the 90K gene. In A, EMSA of nuclear extracts from cells maintained in 5H medium (no TSH) using as probes the radiolabeled double-
strand oligonucleotides with the sequence of Oligo I or the ones with 2 bp substitutions reported in the lower diagram of Fig. 2. In B, EMSA of
nuclear extracts from cells treated with TGF-β1 or TSH and incubated with Oligo I as a probe. In C, EMSA of nuclear extracts from cells treated
with TGF-β1 using Oligo I as probe and each of the double-strand oligonucleotides depicted in the bottom as competitor of complex formation, i.e.,
Oligo I, with the potential CRE or FAST-1 (FBE) binding sites boxed, Oligo CRE, an unrelated oligonucleotide containing the consensus sequence for
CRE, and Oligo FBE, an unrelated oligonucleotide with the consensus sequence for FBE. Nucleotides in Oligo I that are the same as the CRE are noted
with dark circles; nucleotides in Oligo I that are the same as the FBE are noted with asterisks, In D, EMSA of nuclear extracts from TGF-β1-treated cells
incubated with the indicated probes, competitors (20× concentration over labeled probe) or antisera (control, anti-USF1 or anti-USF2). CEM is Oligo I
with 2 bp mutations in the E-box; EWT is an oligonucleotide with a consensus E-box but no other sequence homology to Oligo I; EM is an unrelated
oligonucleotide with a mutation in the E-box. The lowest arrow on the right denotes the native complex; the two upper arrows denote the
supershifted complexes. In E, EMSA of nuclear extracts from TGF-β1-treated cells incubated with Oligo I or EWT used as probes. In lanes 4 and 6, they
were respectively incubated with recombinant USF1 (rUSF1). In F, rat FRTL-5 cells were co-transfected with the pGL3 vector containing the P2
construct of the rat 90K gene and the plasmid containing the full-length cDNAs encoding USF1 (pUSF1) or USF2 (pUSF2) or the control vector pCMV-
tag2A (control plasmid) or nothing (no plasmid). pSVGH was added to measure transfection efficiency. Values were normalized for cell protein and
growth hormone activity. In G, human U2OS cells were co-transfected with pGL3 control vector or the pGL3 vector containing the human 90K
minimal promoter (pGL3_hu90K), plus the Renilla luciferase reporter vector pRLTK to measure transfection efficiency, and with pUSF1 or pUSF2 or
control vector as in F. Values were normalized for cell protein and Renilla activity, and expressed as relative to pGL3 control vector with no insert. A
single asterisk (*) denotes a significant TSH-induced decrease in constitutive promoter activity (p < 0.05); two asterisks (**) denote a significant
increase in promoter activity induced by TGF-β1 or by transfection with pUSF1 or pUSF2 (p < 0.01).
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A role of USFs in the TGF-β1 signaling has been already
suggested in studies on the plasminogen activator
inhibitor-1 (PAI-1) gene25–28, also known as SERPINE1,
but so far no other TGF-β-induced gene has been
reported to be dependent on USF activity. The present
report unequivocally, therefore, establishes the impor-
tance of USF family transcription factors in the TGF-
β1 signaling.
Classically, TGF-β1 signaling is mediated by receptor-
associated Smad2 and Smad3 proteins which form com-
plexes with Smad4 and accumulate in the nucleus where
regulates gene expression29,30. Smad2, Smad3, or Smad4
can mediate TGF-β1-induced transcription by binding
directly to DNA in specific Smad Binding Element
(SBE)31,32. No SBE site exists in 90K minimal promoter,
but we cannot exclude an interaction of USFs with Smads
to act cooperatively elsewhere in the intact 90K gene.
Smads can cooperate with other transcription factors and/
or can interact with co-activator such as FAST-1 to
activate transcription33,34. Since a potential FAST-1 con-
sensus sequence was present in 90K minimal promoter,
we specifically excluded FAST-1 as a mediator of the
TGF-β1 action on 90K gene. The role of the Smad system
in the TGF-β1 regulation of 90K gene described herein
remains to be defined, even though Smad-independent
pathways have been described35,36.
The effect of TGF-β1 to increase 90K gene expression is
quite surprisingly given that TGF-β1 is a suppressor of the
immune system2,3 and decreases MHC class I expression
in FRTL-515, while 90K is an immune-stimulator and
increases MHC class I. The finding that USFs are directly
involved in the TGF-β1 regulation of 90K gene provides a
mechanistic explanation: TGF-β1 suppresses MHC class I
while increasing 90K because different transcription fac-
tors are involved in the regulation of the two genes. In
fact, in FRTL-5 cells, TGF-β1 has been shown to decrease
MHC class I gene expression by regulating diverse trans
factor interactions with two elements located within the
“hormonal regulatory region” of its promoter (−203 to
−90 bp)15. The first element, called Enhancer A (−180 to
−170 bp), can interact with either an inducer factor, the
heterodimer NF-kB p50/fra-2 (MOD-1), or an inhibitor
factor, the heterodimer NF-kB p50/p65. TGF-β1 reduces
the interaction of MOD-1 with Enhancer A while
increasing that of NF-kB p50/p65. Both, reduced MOD-1
and increased p50/p65, suppress class I expression15. The
second element, called downstream regulatory element
(DRE) (−127 to −90 bp) is the binding site of the
Fig. 4 Genomic ChIP-seq reveals that USFs bind the E-box present in the promoter region of the human 90K (LGALS3BP) gene. ChIP-seq
analysis was performed in the publicly available ENCODE platform. Search parameters were the human embryonic cells H1, USF1 as a transcription
factor, and LGALS3BP as the target gene. Six different experiments showed a peak region in the LGAL3BP promoter in Chromosome 17, automatically
aligned. The platform provided also the number of nucleotide position in the chromosome. The highest point of the peaks overlapped with the
consensus motif CANNTG binding site for USF, depicted on the top. The arrow indicates the direction of gene transcription.
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inhibitor factor TSEP-1, a ubiquitously-expressed Y-box
protein. TGF-β1 increases the binding of TSEP-1 to DRE
and, as a consequence, suppresses class I expression15.
These interactions appear to counteract or dominate the
inductive effect of 90K to increase class I.
In addition, a functional explanation can be provided
for the effect of TGF-β1 on MHC class I and 90K: the
upregulation of 90K expression is not related to the
immune response but may reflect the TGF-β1-induced
cellular microenvironment modifications that facilitate
cancer progression. In fact, experimental and clinical data
indicate that 90K is implicated in tumor invasion and
metastases, probably as a result of its ability to promote
cell-to-cell and cell-to-extracellular matrix (ECM) adhe-
sion9,37,38. Consistently, high expression levels of 90K,
both in serum or in tumor cell, have been observed in
patients with different types of cancer and were asso-
ciated with a higher incidence of metastasis and poor
prognosis39–41.
Similarly, TGF-β1 is increased in most human cancer,
and high expression levels correlate with more
advanced stages of malignancy and decreased survi-
val42–44. The pro-metastatic effect of TGF-β1 is mostly
related to its ability to remodel tumor microenviron-
ment45–48 and to promote epithelial–mesenchymal
transition (EMT)49,50.
We propose that in the context of the changing induced
by TGF-β1 in the tumor microenvironment, the axis
TGF-β1/USF/90K may take a part in the process of tumor
progression. This possibility was further supported by our
analysis of the cBioPortal database showing a significant
increased mortality in patients affected by ccRCC with
high levels of 90K expression in tumor samples. Similarly,
high levels of TGF-β1 or USF1 were associated with a
dismal prognosis. Moreover, a synergistic effect of 90K
and TGF-β1 to predict higher mortality was observed.
Importantly, in this cancer population, 90K levels directly
correlated with TGF-β1 and USFs expression.
Fig. 5 Human 90K (LGALS3BP) expression is associated with poor prognosis and directly correlates with TGF-β1 and USFs. Using the public
cancer database cBioPortal, the TCGA PanCancer Atlas cohort of patients affected by clear cell renal cell carcinoma (ccRCC) was analyzed (N= 512). In
A, Kaplan–Meier curves of disease-specific OS stratified by high (EXP > 1) or low (EXP < 1) expression of LGALS3BP. In B, patients were stratified by
TGF-β1 expression; in C, by USF1 expression; and in D, by concomitant LGALS3BP/TGF-β1 high or low expression. In E, scatterplot correlation
between LGALS3BP and TGF-β1 (left), LGALS3BP and USF1 (middle); LGALS3BP and USF2 (right), as visualized by cBioPortal. In F, table elaborated by
cBioPortal showing tendency of co-occurrence among 90K, TGF-β1, and USF1.
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Notably, the other gene activated by TGF-β1 through
USF is PAI-1, a critical factor in the tumor invasion pro-
gram51–57 and implicated in the TGF-β1-induced EMT58,59.
The importance of TGF-β1 in the process of cancer
invasion and diffusion has led to the development of
pharmacological inhibitors of the TGF-β1 signaling, and
currently, some agents are in the early stages of clinical
trials60. PAI-1 has also been proposed as a target for
cancer therapy61. Similarly, we would propose 90K as
another possible anti-cancer target.
In conclusion, the results of the present study on the
effect of TGF-β1 on 90K transcription and the role of
USF1 and USF2 in the regulation of 90K gene expression
have uncovered a novel possible role for 90K in the
TGF-β1-driven tumor progression program. In this
regard, 90K may become a suitable candidate for anti-
cancer therapy.
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